• 11β-HSD1 Inhibition Reduces Liver Fibrosis via Notch Pathway

  2026-06-08

  A recent study demonstrates that a novel 11β-HSD1 inhibitor significantly alleviates liver fibrosis in a chronic mouse model by suppressing the Notch signaling pathway and increasing NK cell-mediated immune clearance of hepatic stellate cells. These findings provide mechanistic insight into the immunometabolic regulation of fibrosis and highlight new targets for MASLD research.

• Meropenem Trihydrate: Unveiling Metabolomics-Driven Resistan

  2026-06-08

  Explore Meropenem trihydrate, a leading carbapenem antibiotic, through the lens of metabolomics and advanced resistance phenotyping. This article reveals how emerging mass spectrometry innovations reshape research on multidrug-resistant infections.

• Repurposing Safe Drugs to Direct DNA Repair in CRISPR Editin

  2026-06-07

  This study systematically screened over 7,000 FDA-approved drugs to identify modulators of DNA double-strand break (DSB) repair pathways in CRISPR genome editing. The findings provide a resource for rationally influencing gene editing outcomes, enhancing disease models, and developing precision therapies.

• MLKL-Induced Lysosomal Permeabilization Drives Necroptosis v

  2026-06-06

  This study reveals that MLKL polymerization on lysosomal membranes induces permeabilization, leading to the release of cathepsin B (CTSB) and subsequent necroptotic cell death. The findings establish a mechanistic link between MLKL activity, lysosomal disruption, and protease-mediated cell death, providing new avenues for targeted intervention in necroptosis-related diseases.

• AEBSF.HCl: Protocols & Innovations in Protease Inhibition Re

  2026-06-05

  AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) redefines serine protease inhibition for cell death and neurodegeneration models. This guide details evidence-based workflows, troubleshooting, and actionable insights for researchers leveraging AEBSF.HCl in advanced protease and amyloid pathway studies.

• Perifosine (KRX-0401): Applied Workflows and Troubleshooting

  2026-06-05

  Perifosine (KRX-0401) is a potent, cell-permeable Akt inhibitor that enables precise modulation of apoptosis and radiosensitization in cancer and neuroprotection models. This article provides workflow guidance, troubleshooting strategies, and actionable insights anchored in both experimental data and recent advances in PI3K/Akt/mTOR pathway research.

• PreScission Protease (PSP): Practical Guide for Tag Cleavage

  2026-06-04

  PreScission Protease (PSP) addresses the need for precise, efficient removal of affinity tags from recombinant proteins during purification workflows, especially where retention of native protein structure and function is critical. It is not recommended for applications requiring broad substrate specificity or high-temperature proteolysis.

• Angiotensin I (human, mouse, rat): Molecular Gateway for Pre

  2026-06-04

  Explore how Angiotensin I (human, mouse, rat) enables precision cardiovascular and neuroendocrine research. This in-depth guide uncovers its molecular mechanism, advanced applications, and practical assay optimization, uniquely leveraging recent advances in spectral interference removal.

• Feedback Regulation of Cotton Gland Size and Phytoalexin Syn

  2026-06-03

  Recent research uncovers a negative feedback loop between GoPGF and JAVL that controls pigment gland size and phytoalexin production in cotton. This finding elucidates how cotton balances defense compound biosynthesis and offers new strategies for crop protection.

• NADH (Reduced Nicotinamide Adenine Dinucleotide) in Energy M

  2026-06-03

  NADH, a core coenzyme in cellular energy metabolism, acts as a central electron donor across glycolysis, the TCA cycle, and the mitochondrial electron transport chain. It serves as a sensitive biomarker for metabolic state and is crucial in disease modeling, photocatalytic cancer therapy, and redox signaling research. APExBIO supplies rigorously characterized NADH (CAS No. 58-68-4) for advanced research applications.

• Vernakalant Hydrochloride for Rapid Conversion of Atrial Fib

  2026-06-02

  This phase 3 trial assesses vernakalant hydrochloride, a novel antiarrhythmic, for the rapid pharmacological conversion of atrial fibrillation (AF). The study demonstrates that vernakalant can significantly increase conversion rates and decrease time to sinus rhythm in short-duration AF, offering a potentially safer and more efficient alternative to existing treatments.

• GM 6001 (Galardin): Empowering Precision MMP Inhibition Work

  2026-06-02

  GM 6001 (Galardin) stands out as a nanomolar-potency, broad-spectrum matrix metalloproteinase inhibitor, enabling researchers to dissect extracellular matrix dynamics across tissue repair, cancer biology, and vascular remodeling. This article delivers actionable protocols, troubleshooting insights, and translational perspectives—bridging the latest reference breakthroughs with APExBIO’s rigorously validated GM 6001 reagent.

• Ranolazine: Anti-Ischemic Agent for Cardiac Ischemia Researc

  2026-06-01

  Ranolazine empowers cardiac and metabolic research with dual action—blocking late sodium currents and optimizing substrate metabolism for unparalleled myocardial protection. This article delivers stepwise workflows, protocol enhancements, and troubleshooting tips for robust experimental outcomes. Integrating the latest mechanistic insights, it positions Ranolazine as a cornerstone for translational cardiometabolic studies.

• Sorafenib (BAY-43-9006): Applied Workflows in Cancer & Antiv

  2026-06-01

  Sorafenib (BAY-43-9006) stands out as a multikinase inhibitor bridging advanced cancer biology and emerging host-directed antiviral strategies. This article delivers protocol-level guidance, troubleshooting know-how, and insight into how APExBIO’s Sorafenib empowers both tumor and infectious disease modeling beyond standard applications.

• RITA (NSC 652287): Mechanisms and Strategy for Translational

  2026-05-31

  This thought-leadership article explores the mechanistic role and strategic application of RITA (NSC 652287) in translational cancer biology. We dissect its function as a potent MDM2-p53 interaction inhibitor, review pioneering in vitro and in vivo validation, and offer actionable guidance for researchers seeking to bridge preclinical insight with clinical potential in renal carcinoma and beyond. By integrating recent advances in assay design and translational readouts, we position RITA as a cornerstone for next-generation oncology workflows.

16153 records 2/1077 page Previous Next 12345 下5页 Last page